Update on clopidogrel and dual anti-platelet therapy: neurology

Transcription

1 European Heart Journal Supplements (2006) 8 (Supplement G), G15 G19 doi: /eurheartj/sul049 Update on clopidogrel and dual anti-platelet therapy: neurology Hans-Christoph Diener Department of Neurology, University Duisburg-Essen, Hufelandstrasse 55, Essen, Germany KEYWORDS Stroke; Secondary prevention; Clopidogrel; Acetylsalicylic acid; Combination therapy; Bleeding complications Patients suffering a transient ischaemic attack (TIA) or ischaemic stroke (IS) have a high recurrence risk. The inhibition of platelet function is effective in the reduction of secondary vascular events in patients with TIA or stroke. This is true for acetylsalicylic acid (ASA), clopidogrel, ticlopidine, and the combination of ASA and slowrelease dipyridamole. This review analyses the results of recent trials like clopidogrel as well as the combination of clopidogrel plus ASA. Clopidogrel is superior to ASA in the prevention of vascular events in patients with IS, myocardial infarction, or peripheral arterial disease. The difference is highest for high-risk patients such as diabetics, patients who underwent coronary bypass surgery, and patients with additional vascular events. A prediction model which allows to identify patients in whom clopidogrel is superior to ASA for the secondary prevention of stroke is presented. In high-risk patients with TIA or stroke, the combination of clopidogrel plus ASA is not superior to clopidogrel monotherapy, but results in a higher rate of bleeding complications. Combination therapy is superior to aspirin monotherapy for the prevention of strokes but not for a combined vascular endpoint. Introduction Stroke Patients at risk of ischaemic events Atherosclerosis is a chronic, disseminated process that causes structural changes in the intima and media of large and medium-sized arteries, initially resulting in endothelial abnormalities and eventually producing atherosclerotic plaques. Thrombosis, as the main complication of atherosclerosis, is mainly caused by platelet activation and aggregation arising from disruption of an atherosclerotic plaque. Atherothrombosis leads to local occlusion or distal embolism, the three common clinical manifestations being coronary heart disease [myocardial infarction (MI) and angina pectoris (AP)], peripheral arterial disease (PAD), and cerebrovascular events such as transient ischaemic attacks (TIA) and ischaemic stroke (IS). Corresponding author. address: h.diener@uni-essen.de Acute stroke is increasingly recognized as one of the leading factors of morbidity and mortality worldwide. Its economical burden is among the highest of all diseases. Over the past decades, acute stroke has increasingly being recognized as a medical emergency. Acute, post-acute, and rehabilitation care of stroke patients in specialized wards as well as revascularizing therapies have been shown to be effective in acute IS. IS accounts for 85% of all strokes, whereas the remaining 15% are due to cerebral haemorrhage. Large vessel atherothrombosis, cardiac embolism, and small vessel occlusion each account for around 20% of all strokes, whereas the aetiology is undetermined in 15% and the remaining 5% are due to other defined causes. 1 Especially, in middle-aged men (45 70 years), large vessel disease is a predominant aetiology. Besides a higher risk of recurrent cerebral events, stroke patients are also at high risk of developing cardiac events. 2 & The European Society of Cardiology All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org

2 G16 H.-C. Diener Secondary prevention of stroke with anti-platelet drugs Recurrence risk after TIA or IS ranges from 5 to 20% per year. 1,3,4 The risk is highest immediately after the first event. 5 8 Numerous trials and meta-analyses have left little doubt that anti-platelet therapy effectively reduces stroke risk in patients with prior IS or TIA The latest publication from the Antithrombotic Trialists s Collaboration 9 involves the meta-analysis of 287 trials with patients in comparisons of antiplatelet therapy vs. controls, and in comparisons of different anti-platelet regimens. The main results were summarized as a reduction of serious vascular events [which includes non-fatal MI, non-fatal stroke, or vascular death (VD)] by about 25% (relative percentage). In absolute terms, the events prevented include 3.6% treated for 2 years among those with previous IS or TIA. The absolute benefits substantially outweigh the absolute risks of major extracranial bleeding. Nevertheless, controversies exist. Foremost among them is the debate over the optimal anti-platelet regimen. The majority of research in secondary stroke prevention supports the clinical value of acetylsalicylic acid (ASA). Several key questions, however, remain unanswered. Is the routine use of anti-platelet therapy justified for all eligible patients? Should ASA be used alone or in combination with another anti-platelet agent such as clopidogrel with a different mode of action? Will administration of low-dose ASA reduce the incidence of side effects? Are the new anti-platelet drugs like clopidogrel superior to ASA? This article is an updated version of an earlier review 13 and summarizes the results of recent clinical trials performed with clopidogrel in the context of evolving strategies for stroke prevention. Clinical efficacy Clopidogrel for the prevention of vascular events in patients with IS, MI, or PAD (CAPRIE) The CAPRIE study was the largest study to date that has tested clopidogrel in the setting of stroke patients. 14 It was a randomized, double-blind study, which compared the effects of 75 mg of clopidogrel with 325 mg of ASA once daily. The aim was to reduce a composite endpoint, which consisted of either IS, MI, or VD. A total of patients with a previous MI or IS, or established PAD were randomized. TIA patients were not included into the CAPRIE-trial. After a mean follow-up period of 1.9 years there was a significant absolute risk reduction of 0.5% and a relative risk reduction (RRR) of 8.7% in favour of clopidogrel. Thus, clopidogrel is slightly more effective than ASA in preventing a composite endpoint of vascular events. It is the agent of choice in patients with contraindications to, or adverse effects on, ASA. For the subgroup of patients in the CAPRIE trial with IS (n ¼ 6431) as the qualifying event, the RRR was 7.3% and not statistically significant (95% CI 25.7 to 18.7). However, the CAPRIE study was not designed to specifically address this subgroup of patients. In several post hoc analyses of the CAPRIE trial, the benefit of clopidogrel was demonstrated to be amplified among high-risk subgroups, including patients with a history of previous IS or MI, 15 patients with diabetes, 16 those with prior cardiac surgery, 17 and those receiving lipid-lowering therapy. 18 In the 4496 patients with a history of previous IS or MI before their qualifying event, clopidogrel produced an RRR of 14.9% vs. ASA for the primary CAPRIE endpoint (P ¼ 0.045). 15 This risk reduction translates into a number of patients needed to treat (NNT) of 71 per year with clopidogrel instead of ASA to prevent further vascular events. For comparison, the NNT is 200 patients per year for the overall CAPRIE population. CARESS trial The CARESS trial, in which the combined use of clopidogrel and ASA was significantly more effective than ASA alone in reducing cerebral microemboli measured by transcranial Doppler sonography in patients with recently symptomatic moderate-to-severe carotid stenosis, identified a subgroup of patients in whom combination therapy might be superior to monotherapy with ASA. 19 The number of patients, 110, was too small to reach a significant reduction in clinical endpoints. Numerically, the number of strokes was smaller in the combination group (0 vs. 4). In CARESS, patients received either a loading dose of 300 mg clopidogrel followed by 75 mg for 7 days plus aspirin or aspirin monotherapy. MATCH trial The MATCH (Management of ATherothrombosis with Clopidogrel in High-risk patients with recent TIA or IS) trial was a randomized, double-blind, placebo-controlled trial that compared ASA (75 mg/day) vs. placebo in 7599 high-risk patients with recent TIA or IS and at least one additional vascular risk factor in patients receiving clopidogrel 75 mg/day. 20,21 Additional vascular risk factors were defined as previous IS, previous MI, angina pectoris, diabetes mellitus, or symptomatic PAD within the previous 3 years. The duration of treatment and follow-up was 18 months. The primary endpoint was a composite of IS, MI, VD, or rehospitalization for acute ischaemia (including rehospitalization for TIA, angina pectoris, or worsening of PAD). Five hundred and ninety-six (15.7%) patients reached the primary endpoint in the group receiving ASA plus clopidogrel compared with 636 (16.7%) patients in the clopidogrel alone group [RRR 6.4%, 95% CI 24.6, 16.3; absolute risk reduction 1% (95% CI 20.6, 2.7); Figure 1]. Life-threatening bleedings were significantly higher in the group receiving ASA plus clopidogrel [96 (2.6%) vs. clopidogrel alone 49 (1.3%); (absolute risk increase 1.3%) 95% CI 0.6, 1.9)]. Major bleedings were also increased in the group receiving ASA in addition to clopidogrel but there was no difference in mortality. Adding ASA to clopidogrel in high-risk patients with recent IS or TIA is associated with a

3 Update on clopidogrel and dual anti-platelet therapy G17 Table 1 Stroke prediction model based on the stroke subgroup in the CAPRIE trial Risk factors Points,65 years years 1.75 years 2 Hypertension (Yes) 1 Diabetes (Yes) 1 Previous MI 1 Other cardiovascular disease (except MI and AF) 1 PAD 1 Smoker (Yes) 1 Additional TIA or IS in addition to qualifying event 1 Figure 1 Patients remaining event-free over time for the primary endpoint (MI, IS, CVD, or rehospitalization due to ischaemic event) in the MATCH trial; intention-to treat population. non-significant difference in terms of major vascular events. However, the risk of life-threatening and major bleeding is increased by the addition of ASA. Predefined subgroup analyses were unable to identify a group of patients were the benefit of combination therapy would outweigh the bleeding risk. The benefit of the combination therapy was highest in patients randomized early after the qualifying event, whereas the differences in bleeding complications emerged only after 3 months. Theoretically, this would indicate that there is a window of opportunity for short-term use of the combination. This, however has to be investigated in a separate trial (FASTER, see below). CHARISMA study The CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance) study, which has recruited patients investigated the role of clopidogrel in both primary and secondary prevention. 22,23 The target study population was one at high risk of atherothrombotic events subjects have documented cerebrovascular, cardiovascular, or PAD. However, subjects with vascular risk factors without a documented event were also enrolled (primary prevention). CHARISMA compared the combination of clopidogrel plus ASA with ASA plus placebo. The rate of the primary efficacy endpoint (composite of MI, IS, or death from cardiovascular causes) showed a RRR of 7% in favour of the combination therapy. 24 This difference was not significant. The only secondary endpoint which showed a significant benefit of combination over monotherapy was non-fatal stroke (150/189 strokes). The results for the patients with stroke as a qualifying event are not yet published. Figure 2 Annual event rate for IS (%) in the MATCH trial gained from the IS population according to the risk score (see Table 1). Please note that the risk scores of 7 and 8 are based on small patient numbers and have wide confidence intervals. Risk model to identify patients at high risk for stroke recurrence Based on a subgroup analysis of the stroke cohort in the CAPRIE trial 15 and the risk factors identified by logistic regression analysis, we developed a predictive model. 13 As shown in Table 1, we assigned points to certain baseline variables and risk factors. The maximal possible score is 10. Rates for recurrent strokes were calculated for each risk factor group separately for ASA and clopidogrel. Overall, the patient population can be separated at an annual stroke risk of smaller or grater than 4% into a low- and a high-risk group. As can be seen from Figure 2, in the low-risk group, there is no difference between ASA and clopidogrel. In the high-risk group (3 6 points), clopidogrel is superior to ASA. The very high-risk group (.6 points) contains few patients and the results have wide confidence intervals. These results clearly favour a strategy in which the stroke recurrence risk guides the decision to use either ASA or clopidogrel for secondary stroke prevention. Ongoing trials The Fast Assessment of Stroke and TIA to prevent Early Recurrence trial (FASTER) will focus on clopidogrel and

4 G18 H.-C. Diener Table 2 Ongoing and planned clinical trials of anti-platelet therapy in stroke prevention [after (Hankey, 2004 #1)] Trial Patients Onset Interventions Primary endpoint Sample size ARCH TIA or IS and aortic arch plaque (14 mm) 0 6 months Clopidogrel 75 mg þ ASA mg vs. warfarin ACTIVE AF (high-risk) Clopidogrel þ ASA vs. warfarin Clopidogrel þ ASA vs. ASA Irbesartan vs. Placebo FASTER TIA or minor IS, Treatment within 12 h after symptom onset 0 12 h Clopidogrel 300 mg loading dose, 75 mg/day vs. placebo. ASA for all patients. Simvastatin 40 mg vs. placebo ProFESS IS 0 90 days Clopidogrel vs. Dipyridamole þ ASA; Telmisartan vs. Placebo SPS3 Small subcortical stroke (MRI) MMSE months Clopidogrel vs. Placebo ASA for all patients IS, MI, VD, or emboli IS, MI, VD (þ emboli for the comparisons between Clopidogrel þ ASA vs. ASA and between Clopidogrel þ ASA vs. warfarin) Stroke at 90 days, combined outcome of myocardial infarction, stroke, or VD at 90 days, stroke severity First recurrent stroke Stroke ASA in the setting of TIA. In this trial, a loading dose of 300 mg clopidogrel is used. A secondary consideration is whether simvastatin is superior to placebo. The primary endpoint is the 90-day risk of stroke. Inclusion time 12 h after a TIA is short. Therefore, FASTER will focus on early secondary prevention (Table 2). The SPS3 (Secondary Prevention of Small Subcortical Strokes) trial investigates not only whether recurrent stroke can be avoided but also whether dementia a high risk in this population can be prevented. Around 2500 patients with small subcortical strokes will be included; those with cardioembolic, cortical or haemorrhagic stroke are excluded. The trial has two treatment arms. In the anti-platelet study, patients will be randomized to ASA and placebo or ASA and clopidogrel. The other treatment arm investigates moderate vs. aggressive blood pressure control. The ongoing PROFESS trial will recruit patients with IS and compare 75 mg clopidogrel with the combination of low-dose ASA with slow-release dipyridamole. This trial is supposed to identify subgroups of patients who might benefit more from one treatment regimen than the other based on risk factors and concomitant diseases. Conclusions Clopidogrel is effective in the prevention of vascular events in high-risk patients and, as shown in subgroup analyses of CAPRIE, this is especially true for people with PAD or diabetes mellitus. A stroke recurrence prediction model offers guidance on which patients should receive ASA or clopidogrel for secondary stroke prevention. Clopidogrel has fewer gastrointestinal side-effects than ASA. However, it does not demonstrate difference from ASA in patients with IS overall. Presently, the combination of clopidogrel plus ASA cannot be recommended in high-risk patients with TIA or IS. In this group, the combination is not superior to clopidogrel or aspirin monotherapy but leads to more bleeding complications. In the future, trials may show that the combination of clopidogrel plus ASA is superior to ASA or clopidogrel alone in the secondary prevention of stroke in high-risk patients, vascular events after TIA, lacunar stroke, and vascular dementia. However, this higher efficacy may come at the price of a higher bleeding rate. The results of ongoing trials, including PROFESS, will help us assess this risk benefit ratio accurately. Acknowledgements Financial support for research projects was provided by Astra/ Zeneca, GSK, Böhringer Ingelheim, Novartis, Janssen-Cilag, sanofi-aventis. The Department of Neurology at the University, Duisburg-Essen received research grants from the German Research Council (DFG), the German Ministry of Education and Research (BMBF), the European Union, the Bertelsmann Foundation, and the Heinz-Nixdorf Foundation. Conflict of interest: H.-C.D. received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from Abbott, AstraZeneca, Bayer Vital, Böhringer Ingelheim, D-Pharm, Fresenius, GlaxoSmithKline, Janssen Cilag, MSD, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, sanofiaventis, Sankyo, Servier, Solvay, Wyeth, Yamaguchi. References 1. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener H. Risk factors, outcome, and treatment in subtypes of ischaemic stroke: the German stroke data bank. Stroke 2001;32:

5 Update on clopidogrel and dual anti-platelet therapy G19 2. Hankey GJ. Stroke. How large a public health problem, and how can the neurologist help? Arch Neurol 1999;56: Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992;49: Weimar C, Kraywinkel K, Rodl J, Hippe A, Harms L, Kloth A, Diener HC, German Stroke Data Bank Collaborators. Etiology, duration, and prognosis of transient ischaemic attacks: an analysis from the German Stroke Data Bank. Arch Neurol 2002;59: Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000;284: Weimar C, Roth MP, Zillessen G, Glahn J, Wimmer ML, Busse O, Haberl RL, Diener HC. German Stroke Data Bank Collaborators. Complications following acute ischaemic stroke. Eur Neurol 2002;48: Lovett J, Coull A, Rothwell P. Early risk of recurrence by subtype of ischaemic stroke in population-based incidence studies. Neurology 2004;62: Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 2005;64: Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;524: Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308: Antiplatelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296: Patrono C, Roth GJ. Aspirin in ischaemic cerebrovascular disease. Stroke 1996;27: Diener HC, Ringleb PA, Savi P. Clopidogrel for secondary prevention of stroke. Expert Opin Pharmacother 2005;6: CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348: Ringleb P, Bhatt D, Hirsch A, Topol E, Hacke W. Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischaemic events. Stroke 2004;35: Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90: Bhatt D, Chew D, Hirsch A, Ringleb P, Hacke W, Topol E. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103: Bhatt D, Foody J, Hirsch A, Ringleb P, Hacke W, Topol E. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherothrombosis. J Am Coll Cardiol 2000;35(Suppl. A): Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111: Diener H, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht H-J, on behalf of the MATCH Investigators. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cererbrovasc Dis 2004;17: Diener H, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht H-J, on behalf of the MATCH Investigators. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results. Lancet 2004;364: Bhatt DL, Topol EJ; on behalf of the CHARISMA Executive Committee. Clopidogrel added to aspirin alone in secondary prevention and highrisk primary prevention. Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004;148: Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2005;150: Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, for the CHARISMA trial. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354: